Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Incyte (INCY) PT Raised to $146 at BMO Capital
May 5, 2017 9:13 AM EDTBMO Capital raised its price target on Incyte (NASDAQ: INCY) to $146.00 (from $144.00) while maintaining a Outperform rating following strong Jakafi results in Q1.
Analyst M. Ian Somaiya commented, "While polycythemia vera (PV) continues to be a growth driver, graft vs host... More
Incyte (INCY) Tops Q1 EPS by 4c
May 4, 2017 7:15 AM EDTIncyte (NASDAQ: INCY) reported Q1 EPS of ($0.96), $0.04 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $384.08 million versus the consensus estimate of $358.27 million.
Cash, cash equivalents and marketable securities position As of March 31, 2017, cash, cash equivalents and marketable securities... More
